KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for Emergent BioSolutions (EBS) over the last 8 years, with Q3 2017 value amounting to $413752.0.

  • Emergent BioSolutions' Gains from Sales and Divestitures changed N/A to $413752.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $413752.0, marking a year-over-year change of. This contributed to the annual value of $422515.0 for FY2015, which is 1703.69% up from last year.
  • According to the latest figures from Q3 2017, Emergent BioSolutions' Gains from Sales and Divestitures is $413752.0.
  • In the past 5 years, Emergent BioSolutions' Gains from Sales and Divestitures ranged from a high of $422515.0 in Q4 2015 and a low of $291619.0 during Q1 2013
  • For the 5-year period, Emergent BioSolutions' Gains from Sales and Divestitures averaged around $360015.9, with its median value being $353117.0 (2016).
  • Per our database at Business Quant, Emergent BioSolutions' Gains from Sales and Divestitures skyrocketed by 143483.68% in 2013 and then surged by 235.58% in 2014.
  • Emergent BioSolutions' Gains from Sales and Divestitures (Quarter) stood at $337498.0 in 2013, then rose by 6.97% to $361010.0 in 2014, then rose by 17.04% to $422515.0 in 2015, then dropped by 4.24% to $404585.0 in 2016, then rose by 2.27% to $413752.0 in 2017.
  • Its Gains from Sales and Divestitures stands at $413752.0 for Q3 2017, versus $404585.0 for Q2 2016 and $353117.0 for Q1 2016.